Skip Ribbon Commands
Skip to main content

My child has

Because childhood should be simple ...

Lauren J. Akers, DO
Cook Children's Physician Network

Lauren Akers
Specialties:Hematology/Oncology
Education:Nova Southeastern University, College of Osteopathic Medicine, Florida
Residency:Children's Hospital of Austin
Fellowship:Children's Cancer Hospital, Houston
Board Certified:Pediatrics and Pediatric Hematology/Oncology

 


Locations:

1500 Cooper St.
Fort Worth, TX 76104
(682) 885-4007
Driving directions
1600 W. Northwest Hightway Ste. 500
Grapevine, TX 76054
(817) 310 0024
Driving directions
1002 S. Abe St., Ste. B
San Angelo, Texas 76903
325-655-4675
Driving directions

Publications:

Kannan, S., Sutphin, R. M., Hall, M. G., Golfman, L. S., Fang, W., Nolo, R. M., AKERS, L. J., Hammitt, R. A., McMurray, J. S., Kornblau, S. M., Melnick, A. M., Figueroa, M. E., & Zweidler-McKay, P. A. (2013). Notch activation inhibits AML growth and survival: A potential therapeutic approach. The Journal of Experimental Medicine, 210(2), 321-337.

Levy, A. G., Zage, P. E., AKERS, L. J., Ghisoli, M. L., Chen, Z., Fang, W., Kannan, S., Graham, T., Zeng, L., Franklin, A. R., Huang, P., & Zweidler-McKay, P. A. (2012). The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Investigational New Drugs, 30(1), 191-199.

MURRAY, J. C., AKERS, L. J., HEYM, K., & Biegel, J. (2012). Sequential childhood neoplasms-leukemia following central nervous system tumors. Paper presented at the 25th Annual Meeting of the American Society of Pediatric Hematology/Oncology (ASPHO 2012), New Orleans, LA. Mary 9-12, 2012, 58(7) 1056

AKERS, L. J., Fang, W., Levy, A. G., Franklin, A. R., Huang, P., & Zweidler-McKay, P. A. (2011). Targeting glycolysis in leukemia: A novel inhibitor 3-BrOP in combination with rapamycin. Leukemia Research, 35(6), 814-820.

Levy, A., AKERS, L. J., Ghisoli, M. L., Graham, T. C., Zeng, L., Nolo, R., Zage, P. E., Fang, W., Kannan, S., Franklin, A. R., Huang, P., & Zweidler-McKay, P. A. (2009). Neuroblastoma and the Warburg effect: The novel glycolysis inhibitor 3-BrOP is effective in vitro and in vivo. 22nd Annual Meeting of the American Society of Pediatric Hematology/Oncology, San Diego, CA. April 22-25, 2009

AKERS, L. J., Franklin, A. R., Fang, W., Levy, A. G., Huang, P., & Zweidler-McKay, P. A. (2008). The novel glycolysis inhibitor, 3-BrOP, has broad activity against acute lymphoblastic leukemias (ALL), and synergizes with rapamycin. 21st Annual Meeting of the American Society of Pediatric Hematology/Oncology, Cincinnati, OH. May 14-17, 2008 

AKERS, L. J. (2007). The novel glycolysis inhibitor, 3-BrOP, offers a potential therapeutic approach in ALL and AML. 20th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Toronto, Ontario Canada. May 3-7, 2007

AKERS, L. J., Franklin, A. R., Fang, W., Levy, A. G., Huang, P., & Zweidler-McKay, P. A. (2007). The novel glycolysis inhibitor, 3-BrOP, has broad activity against acute lymphoid leukemias and potentiates methotrexate and rapamycin. 49th ASH (American Society of Hematology) Annual Meeting and Exposition, Atlanta, GA. December 8-11, 2007, 110(11) Abs. 4203.

AKERS, L. J., & Hughes, D. P. M. (2007). Decreasing clearance time of high-dose methotrexate following pre-treatment with folic acid. 20th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Toronto, Ontario Canada. May 3-7, 2007 

Rocket Fuel